291 related articles for article (PubMed ID: 12149047)
1. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
Wagstaff AJ; Goa KL
Drugs; 2002; 62(12):1805-37. PubMed ID: 12149047
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
Wagstaff AJ; Goa KL
Treat Endocrinol; 2002; 1(6):411-4. PubMed ID: 15832493
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Lebovitz HE; Kreider M; Freed MI
Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
8. A review of rosiglitazone in type 2 diabetes mellitus.
Werner AL; Travaglini MT
Pharmacotherapy; 2001 Sep; 21(9):1082-99. PubMed ID: 11560198
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.
Gegick CG; Altheimer MD
Endocr Pract; 2001; 7(3):162-9. PubMed ID: 11421562
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone : a review of its use in type 2 diabetes mellitus.
Deeks ED; Keam SJ
Drugs; 2007; 67(18):2747-79. PubMed ID: 18062722
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Diamant M; Heine RJ
Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone.
Goldstein BJ
Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.
Malinowski JM; Bolesta S
Clin Ther; 2000 Oct; 22(10):1151-68; discussion 1149-50. PubMed ID: 11110228
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone.
Balfour JA; Plosker GL
Drugs; 1999 Jun; 57(6):921-30; discussion 931-2. PubMed ID: 10400405
[TBL] [Abstract][Full Text] [Related]
17. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
19. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone and pioglitazone: new preparations. Two new oral antidiabetics both poorly assessed.
Prescrire Int; 2002 Dec; 11(62):170-6. PubMed ID: 12469695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
